<HTML><BODY style="word-wrap: break-word; -khtml-nbsp-mode: space; -khtml-line-break: after-white-space; "><DIV><FONT class="Apple-style-span" face="Verdana"><FONT class="Apple-style-span" size="2"><SPAN class="Apple-style-span" style="font-size: 10px;">To read this in html, click here: </SPAN></FONT></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><A href="http://www.maps.org/news"><FONT class="Apple-style-span" size="2"><SPAN class="Apple-style-span" style="font-size: 10px;">http://www.maps.org/news</SPAN></FONT></A></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">MAPS Members, Supporters, and Friends,</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">I am pleased to announce that </FONT><B><FONT class="Apple-style-span" face="Verdana">tomorrow</FONT></B><FONT class="Apple-style-span" face="Verdana"> a letter will be delivered to DEA Administrator Karen Tandy signed by </FONT><B><FONT class="Apple-style-span" face="Verdana">45</FONT></B><FONT class="Apple-style-span" face="Verdana"> members of the U.S. House of Representatives. The letter urges her agency to accept DEA Administrative Law Judge Mary Ellen Bittner's recommendation that would it be in the public interest to license Professor Lyle Craker's proposed MAPS-sponsored medical marijuana production facility at UMass-Amherst. This letter demonstrates to DEA that there is a growing political will to end the federal government's monopoly on the supply of marijuana that can be used in FDA-approved research.</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">As you know, MAPS is the only membership-based organization working to develop marijuana and psychedelics into legal, FDA-approved prescription medicines. If you think the world would be a better place if MAPS is empowered to implement its plans, please consider supporting our work by making a donation or Webstore purchase today at: </FONT><A href="http://www.maps.org/donate"><FONT class="Apple-style-span" face="Verdana">http://www.maps.org/donate</FONT></A></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Without further adieu, here's the news:</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">1</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> Fall 2007 </FONT><I><FONT class="Apple-style-span" face="Verdana">MAPS Bulletin</FONT></I><FONT class="Apple-style-span" face="Verdana"> in the Mail to MAPS Members</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">2</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> Forty-Five U.S. Representatives Send Letter to DEA in Support of Medical Marijuana Research</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">3</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> FDA Reviews US MDMA/PTSD Protocol Amendment</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">4</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> Key Changes to MDMA/End-of-Life Anxiety Receive IRB Approvals, Awaiting FDA Approval</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">5</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> New MAPS-Sponsored Psilocybin/End-of-Life Anxiety Study Submitted to FDA</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">6. </FONT></B><FONT class="Apple-style-span" face="Verdana">MAPS-Sponsored LSD Study Featured on Swiss TV News, Scheduled for Another Ethics Committee Review</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">7</FONT></B><B><FONT class="Apple-style-span" face="Verdana">. </FONT><SPAN class="Apple-style-span" style="font-weight: normal;"><FONT class="Apple-style-span" face="Verdana">MAPS Receives $35K Grant for Operational Expenses from Donor-Advised Tides Foundation Fund, $20K Donation from Anonymous Donor</FONT></SPAN></B></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">8</FONT></B><B><FONT class="Apple-style-span" face="Verdana">. </FONT></B><I><FONT class="Apple-style-span" face="Verdana">Chemistry World</FONT></I><FONT class="Apple-style-span" face="Verdana"> Publishes Feature Article on Medical Research with Psychedelics</FONT><FONT class="Apple-style-span" face="Verdana"><B></B></FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">9</FONT></B><B><FONT class="Apple-style-span" face="Verdana">. </FONT></B><FONT class="Apple-style-span" face="Verdana">New Ayahuasca Study Confirms Therapeutic Potential </FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">10</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> MAPS Facilitates Harm Reduction Services at Burning Man Festival</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">11</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> Audio Recordings of Presentations Available from Women's Visionary Congress</FONT><DIV><B><FONT class="Apple-style-span" face="Verdana">12</FONT></B><B><FONT class="Apple-style-span" face="Verdana">.</FONT></B><FONT class="Apple-style-span" face="Verdana"> Horizons: A One-Day Psychedelic Conference in Manhattan, Oct. 27</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">13</FONT></B><B><FONT class="Apple-style-span" face="Verdana">. </FONT></B><FONT class="Apple-style-span" face="Verdana">Join MAPS at the International Drug Policy Reform Conference in New Orleans, Dec. 5-8</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">14. </FONT></B><FONT class="Apple-style-span" face="Verdana">Join MAPS at the World Psychedelic Forum, March 21-24</FONT></DIV><FONT class="Apple-style-span" face="Verdana"><B></B></FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana">15. </FONT></B><FONT class="Apple-style-span" face="Verdana">Psychedelic Researcher John Beresford Dies</FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana">1. </FONT><B><FONT class="Apple-style-span" face="Verdana">Fall 2007 </FONT></B><B><I><FONT class="Apple-style-span" face="Verdana">MAPS Bulletin</FONT></I></B><B><FONT class="Apple-style-span" face="Verdana"> in the Mail to MAPS Members</FONT></B><FONT class="Apple-style-span" face="Verdana"><B></B></FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR style=""></FONT></B><DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">If you are a MAPS member, in the next 2-3 weeks you will receive the Fall 2007 issue of the </FONT><I><FONT class="Apple-style-span" face="Verdana">MAPS Bulletin</FONT></I><FONT class="Apple-style-span" face="Verdana"> in your mailbox. This </FONT><I><FONT class="Apple-style-span" face="Verdana">Bulletin</FONT></I><FONT class="Apple-style-span" face="Verdana"> is a special issue on the theme of "Psychedelics and Self-Discovery." Thank you to the thoughtful and generous MAPS members and supporters who submitted articles for this issue. If you are not a MAPS member and would like to receive a printed copy of the tri-annual </FONT><I><FONT class="Apple-style-span" face="Verdana">MAPS Bulletin</FONT></I><FONT class="Apple-style-span" face="Verdana">, please consider joining MAPS today: </FONT><A href="http://www.maps.org/donate"><FONT class="Apple-style-span" face="Verdana">http://www.maps.org/donate</FONT></A><FONT class="Apple-style-span" face="Verdana"> </FONT></DIV></DIV></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">2. </FONT><B><FONT class="Apple-style-span" face="Verdana">Forty-Five U.S. Representatives Send Letter to DEA in Support of Medical Marijuana Research</FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">Tomorrow, a letter signed by 45 members of the U.S. House of Representatives will be delivered to U.S. Drug Enforcement Administration (DEA) Administrator Karen Tandy urging her agency to license UMass-Amherst professor Lyle Craker to establish the nation's first privately funded research-grade marijuana production facility. The letter was signed by forty-two Democrats and 3 Republicans.</FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"> </FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">The bipartisan letter, co-sponsored by Reps. John Olver (D-MA) and Dana Rohrabacher (R-CA), urges DEA to follow Administrative Law Judge Mary Ellen Bittner's February, 2007 ruling in favor of Prof. Craker. The law judge's ruling is non-binding and DEA has no deadline to decide whether to accept or reject it. </FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">Prof. Craker's ongoing six-year struggle is the focal point of the effort to put marijuana through FDA clinical trials to determine whether it meets federal standards for medical safety and efficacy. If DEA accepts the recommendation, Prof. Craker's proposed MAPS-funded facility would create the necessary independence of supply outside of the NIDA-controlled monopoly to justify the time and expense for MAPS and other organizations to sponsor clinical research evaluating the risks and benefits of marijuana as a potential FDA-approved prescription medicine. NIDA's monopoly has been the key obstruction to FDA drug development research for four decades. </FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">This strong showing was possible because MAPS members expressed support for marijuana research to their Representatives. This strong showing was also possible because MAPS' staff temporarily expanded to include Lauren Anderson Payne, JD, Kelly Burns, Liberty Coalition National Director Michael Ostrolenk, MD, and US Bill of Rights Foundation President Dane Von Breichenruchardt, who worked together with me (Jag Davies) to obtain support from organizations and Congressional Representatives. </FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">Furthermore, this strong showing was possible because our organizational allies and their supporters provided additional support on Capitol Hill, essential know-how, public relations assistance and grassroots mobilization. These organizations include Americans for Safe Access (ASA), American Civil Liberties Union (ACLU), Marijuana Policy Project (MPP), Drug Policy Alliance (DPA), and National Organization for the Reform of Marijuana Laws (NORML), Interfaith Drug Policy Initiative (IDPI), Drug Reform Coordination Network (DRCnet), and Patients out of Time (POT). ASA was particularly helpful and provided a temporary office for Lauren to work from in Washington, D.C., for several months.</FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">MAPS has received recent financial contributions for this effort to pressure DEA to accept Judge Bittner's ruling from the Marijuana Policy Project ($45,000) and the Drug Policy Alliance ($12,500). Philanthropist and MAPS Board member John Gilmore has also donated over $50,000 to date for Prof. Craker's struggle.</FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">On behalf of the MAPS staff, we thank you for helping us orchestrate the multiplicity of efforts that have created this incredible window of opportunity. For background on this case and the latest news, please visit: </FONT><A href="http://www.maps.org/mmj/DEAlawsuit.html"><FONT class="Apple-style-span" face="Verdana">http://www.maps.org/mmj/DEAlawsuit.html</FONT></A></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Last month, MAPS President Rick Doblin, PhD, gave a thorough interview about MAPS' medical marijuana efforts on "Dr. Meg Jordan, Global Medicine Hunter" on the Health Radio network. Click here to listen: <A href="http://www.healthradio.net/component/option,com_mtree/task,viewlink/link_id,3866/Itemid,273">http://www.healthradio.net/component/option,com_mtree/task,viewlink/link_id,3866/Itemid,273</A></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">The full letter to DEA with all 45 signatures is also posted on the MAPS site: <A href="http://www.maps.org/mmj/signonfinal.pdf">http://www.maps.org/mmj/signonfinal.pdf</A></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">3.</FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT><B><FONT class="Apple-style-span" face="Verdana">FDA Reviews US MDMA/PTSD Protocol Amendment</FONT></B><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN><FONT class="Apple-style-span" face="Verdana"><B></B></FONT></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">Michael Mithoefer, MD, and Annie Mithoefer, BSN, have</FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN><FONT class="Apple-style-span" face="Verdana">enrolled 18 out of 20 subjects in their MAPS-sponsored study evaluating MDMA-assisted psychotherapy for subjects with chronic PTSD. </FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN><FONT class="Apple-style-span" face="Verdana">Another two potential subjects are currently in the screening process. The completion of MAPS’ flagship FDA Phase 2 clinical research study is now in sight.</FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">Several weeks ago, MAPS and Dr. Mithoefer submitted a protocol amendment to FDA, seeking approval to treat a 21st subject, a US veteran with PTSD from the Iraq War. We need FDA permission to deviate from our inclusion criteria that requires all PTSD subjects to be treatment-failures from both drug and non-drug treatments.</FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"> </FONT><SPAN style=""><SPAN style=""><FONT class="Apple-style-span" face="Verdana">The request to include a subject who is not a treatment-failure is due to the sad fact that this veteran, like several others with whom we have spoken, has been diagnosed with PTSD but has never been offered treatment by the military. </FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana">We expect to hear from FDA</FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN><FONT class="Apple-style-span" face="Verdana">in a few weeks.</FONT></SPAN></SPAN></SPAN></SPAN></SPAN></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana">4. </FONT><B><FONT class="Apple-style-span" face="Verdana">Key Changes to MDMA/End-of-Life Anxiety Receive IRB Approvals, Awaiting FDA Approval</FONT></B><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Dr. John Halpern of McLean Hospital/Harvard Medical School informed us that he recently received IRB approvals from McLean Hospital and from the Lahey Clinic Medical Center for a series of crucial changes to his protocol, "Phase II Dose-Response Pilot Study of +/-3,4-Methylenedioxymethamphetamine (MDMA)-assisted Psychotherapy in Subjects with Anxiety Associated with Advanced Stage Cancer." Dr. Halpern is the sponsor/investigator for this study, which MAPS helped to initiate. </FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font: normal normal normal 12px/normal Helvetica; min-height: 14px; "><FONT class="Apple-style-span" face="Verdana"><BR style=""></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Dr. Halpern will submit these changes to FDA later this week. If these changes are accepted by FDA, this updated version of the protocol will enable recruitment from a much larger pool of potential subjects and will result in the study's first and subsequent 11 subjects. The main changes include: inclusion of cancer patients still receiving cancer treatments but for palliative purposes only, removal of a cut-off score for the STAI (State Trait Anxiety Inventory), inclusion of the HADS (Hospital Anxiety and Depression Scale), and inclusion of other female co-psychotherapists.</FONT></DIV><FONT class="Apple-style-span" face="Verdana"><B></B></FONT></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana">5. </FONT><B><FONT class="Apple-style-span" face="Verdana">New MAPS-Sponsored Psilocybin/End-of-Life Anxiety Study Submitted to FDA</FONT></B></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Later this week, MAPS will submit an application to FDA this week for a new study evaluating psilocybin-assisted psychotherapy for subjects with end-of-life anxiety secondary to advanced-stage melanoma.</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><SPAN style=""><FONT class="Apple-style-span" face="Verdana">The study will take place in the US and will evaluate nine subjects with anxiety secondary to advanced-stage melanoma. MAPS has been working with the researchers on protocol development for over one year. The protocol was submitted last month to FDA and to an IRB, with the review currently in process. We will be able to post the protocol on the MAPS Website and disclose the names and institutional affiliations of the researchers after the study receives IRB and FDA approval. </FONT></SPAN></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><SPAN style=""><FONT class="Apple-style-span" face="Verdana">The researchers for this study have generously offered to </FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana">volunteer their time, which will reduce overall costs significantly. The estimated budget for this study is $50,000, all of which remains to be raised.</FONT></SPAN></SPAN></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">6. </FONT><B><FONT class="Apple-style-span" face="Verdana">MAPS-Sponsored LSD Study Featured on Swiss TV News, Scheduled for Another Ethics Committee Review</FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">A major Swiss TV news report was broadcast earlier this month about Dr. Peter Gasser's MAPS-sponsored study evaluating LSD-assisted psychotherapy for subjects with end-of-life anxiety secondary to end-stage illness. The report includes a new interview with Albert Hofmann, who rarely speaks publicly due to his fragile health.</FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN></SPAN></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">To see the report (in German, translation in process) please visit: </FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"><A href="http://www.maps.org/avarchive/telebasel_lsdstudy-sept07.wmv">http://www.maps.org/avarchive/telebasel_lsdstudy-sept07.wmv</A></FONT></SPAN></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">Dr. Gasser's protocol will be reviewed again on November 8 by the Swiss Ethics Committee (EC). The EC is reviewing a report about the protocol from a Swiss psychooncologist who raised issues about patient selection (cancer patients v. patients with a range of life-threatening illnesses) and the possibility of measuring any acute traumatic effects of the LSD experience. We expect that this meeting of the EC will resolve the final issues regarding protocol design. </FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">The protocol has already been submitted to SwissMedic, the Swiss equivalent of the FDA. SwissMedic has begun its review and is waiting to consider the outcome of the EC meeting in November. After EC and Swissmedic approval have been obtained, we expect we’ll </FONT><SPAN style="mso-spacerun: yes"><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN><FONT class="Apple-style-span" face="Verdana">need an additional several weeks to obtain final approval from the BAG, </FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana">the Swiss equivalent of DEA. We expect the study to be fully approved by </FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana">January11, 2008, Albert Hofmann’s 102nd Birthday.</FONT></SPAN></SPAN></SPAN></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">For background information about this study, please see:</FONT><FONT class="Apple-style-span" face="Verdana"><O:P style=""></O:P></FONT><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"><A href="http://www.maps.org/research/cluster/psilo-lsd/#swlsd">http://www.maps.org/research/cluster/psilo-lsd/#swlsd</A></FONT></SPAN></DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">MAPS has already raised $$43,000 for this study from the sale of Albert Hofmann-signed art and books, but an additional</FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">$160,000 is still needed. In addition to general donations for <SPAN style="">operational expenses, MAPS also accepts restricted donations for</SPAN></FONT></SPAN></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana">specific research projects.</FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">To make a restricted donation, or for purchase information regarding Albert Hofmann-signed books and art, please visit: <A href="http://www.maps.org/catalog">http://www.maps.org/catalog</A></FONT></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT><FONT class="Apple-style-span" face="Verdana"><O:P></O:P></FONT></SPAN></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">7.</FONT><B><FONT class="Apple-style-span" face="Verdana"> </FONT></B><B><FONT class="Apple-style-span" face="Verdana">MAPS Receives $35K Grant from Donor-Advised </FONT></B><B><FONT class="Apple-style-span" face="Verdana">Tides Foundation </FONT></B><B><FONT class="Apple-style-span" face="Verdana">Fund, $20K Donation from Anonymous Donor</FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Earlier this month, MAPS received two critical donations for operational expenses. Last month, an anonymous donor contributed $20,000 directly to MAPS. Then, earlier this month, another anonymous donor generously contributed $35,000, through a fund at the Tides Foundation. We are deeply grateful to these two individuals for their support and generosity. Since most large donations are earmarked for specific research projects, donations for operational expenses are especially helpful and appreciated. </FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">8. </FONT><I><B><FONT class="Apple-style-span" face="Verdana">Chemistry World</FONT><SPAN class="Apple-style-span" style="font-style: normal;"><FONT class="Apple-style-span" face="Verdana"> Publishes Feature Article on Medical Research with Psychedelics</FONT></SPAN></B></I></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><I><FONT class="Apple-style-span" face="Verdana">Chemistry World</FONT></I><FONT class="Apple-style-span" face="Verdana"> magazine recently published a comprehensive feature-length story about the "resurgence of medical hallucinogens." MAPS President Rick Doblin is quoted throughout the article. Click here to read: <A href="http://maps.org/media/chemworldsep07.pdf">http://maps.org/media/chemworldsep07.pdf</A></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">9. </FONT><B><FONT class="Apple-style-span" face="Verdana">New Ayahuasca Study Confirms Therapeutic Potential </FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">A study recently published in the </FONT><I><FONT class="Apple-style-span" face="Verdana">Journal of Ethnopharmacology</FONT></I><FONT class="Apple-style-span" face="Verdana"> has demonstrated that the South American psychedelic plant brew </FONT><I><FONT class="Apple-style-span" face="Verdana">ayahuasca</FONT></I><FONT class="Apple-style-span" face="Verdana"> can alleviate signs of anxiety, panic, and hopelessness. The international quintet of researchers conducting the study, which included noted DMT researcher Rick Strassman, MD, concluded that: </FONT><FONT class="Apple-style-span" face="Verdana"><FONT class="Apple-style-span" color="#0025CF"></FONT></FONT></DIV><DIV><FONT class="Apple-style-span" color="#0025CF"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></FONT></DIV><DIV><FONT class="Apple-style-span" color="#000000"><FONT class="Apple-style-span" face="Verdana">"While under the acute effects of ayahuasca, participants scored lower on the scales for panic and hopelessness related states. Ayahuasca ingestion did not modify state- or trait-anxiety. The results are discussed in terms of the possible use of ayahuasca in alleviating signs of hopelessness and panic-like related symptoms."</FONT></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">To read the full study, see: </FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><A href="http://www.maps.org/media/ayahuasca-jep.pdf"><FONT class="Apple-style-span" face="Verdana">http://www.maps.org/media/ayahuasca-jep.pdf</FONT></A></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">10. </FONT><B><FONT class="Apple-style-span" face="Verdana">MAPS Facilitates Harm Reduction Services at Burning Man Festival</FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">From Aug. 26-Sep. 2, as part of MAPS' educational outreach and harm reduction mission, for the fifth year in a row MAPS assisted Burning Man's Black Rock Rangers by coordinating a team of trained volunteers at Burning Man's "Sanctuary." </FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Sanctuary is a project led by the Black Rock City Rangers to provide a safe space for people who are undergoing emotional or psychological crises or who need non-medical assistance. MAPS volunteers lend their support and are trained to work with visitors undergoing psychedelic emergencies. MAPS staffer Valerie Mojeiko coordinated the training of over 30 volunteers for Sanctuary, assisted by about eight core staff with psychedelic psychotherapy experience. Over 100 people going through difficult emotional and psychological experiences, some psychedelic-related, and some not, were cared in for Sanctuary over the course of the week-long event. </FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">11. </FONT><B><FONT class="Apple-style-span" face="Verdana">Audio Recordings of Presentations Available from Women's Visionary Congress</FONT></B><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">From July 27-29, 2007, MAPS co-sponsored the Women's Visionary Congress, a unique gathering of women working to reform psychedelic and marijuana policy and to re-define society's understanding of these drugs. For those of you who were unable to attend, or for those of you who were there and would like to listen to a particular presentation again, we have good news: the audio recordings are available. To listen to a panel, please visit: </FONT><A href="http://www.maps.org/avarchive/wvc_audio.html"><FONT class="Apple-style-span" face="Verdana">http://www.maps.org/avarchive/wvc_audio.html</FONT></A></DIV></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Of particular relevance to MAPS' work is Panel #4, moderated by MAPS Clinical Research Associate Valerie Mojeiko. The panel featured Annie Mithoefer, BSN (MAPS-sponsored MDMA/PTSD therapist), Amy Emerson (MAPS' volunteer clinical monitoring expert), and June May Ruse (co-author for MAPS' MDMA/PTSD treatment manual). </FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">12. </FONT><B><FONT class="Apple-style-span" face="Verdana">Horizons: A One-Day Psychedelic Conference in Manhattan, Oct. 27</FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Join MAPS President Rick Doblin, MAPS-sponsored researchers Michael Mithoefer and Andrew Sewell, artists Alex & Allyson Gray, Drug Policy Alliance Executive Director Ethan Nadelmann, and others at "Horizons: Contemporary Perspectives on Psychedelics" on October 27 at Judson Memorial Church in Greenwich Village from 1-6 pm. Proceeds from the conference will be donated to MAPS and the other non-profit organizations involved with the event.</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">For information on the conference, speaker bios, and tickets, please visit: </FONT><A href="http://www.horizonsnyc.org/index.html"><FONT class="Apple-style-span" face="Verdana">http://www.horizonsnyc.org/index.html</FONT></A></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">13. </FONT><B><FONT class="Apple-style-span" face="Verdana">Join MAPS at the International Drug Policy Reform conference in New Orleans, Dec. 5-8</FONT></B></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><B><I><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></I></B></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">This December 5-8, MAPS will join hundreds of other drug policy reformers in New Orleans for the biennial International Drug Policy Reform conference, hosted by the Drug Policy Alliance (DPA). MAPS Director of Development Troy Dayton and I will be attending the conference to present MAPS' work. DPA is the leading organization in the US working to end the War on Drugs and envision new drug policies based on science, compassion, health and human rights. We are grateful to have DPA as an ally in the struggle to create rational alternatives to prohibition-based policy.</FONT></DIV><P style="margin: 0.0px 0.0px 0.0px 0.0px"><FONT class="Apple-style-span" face="Verdana"> </FONT></P><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">If you are a MAPS supporter who will be attending, we are looking for volunteers to help staff the MAPS table during the conference. If you are interested, please contact me by replying to this email.</FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">For more information about DPA and the 2007 International Drug Policy Reform conference: </FONT><A href="http://kessjones.com/conf07/"><FONT class="Apple-style-span" color="#0027DF"><FONT class="Apple-style-span" face="Verdana">http://kessjones.com/conf07/</FONT></FONT></A></DIV><P style="margin: 0.0px 0.0px 0.0px 0.0px"><FONT class="Apple-style-span" face="Verdana"> </FONT></P><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">To read my review of the 2005 conference in the Spring 2006 </FONT><I><FONT class="Apple-style-span" face="Verdana">MAPS Bulletin</FONT></I><FONT class="Apple-style-span" face="Verdana">, see: </FONT><A href="http://maps.org/news-letters/v16n1-html/building_a_movement.html"><FONT class="Apple-style-span" color="#0027DF"><FONT class="Apple-style-span" face="Verdana">http://maps.org/news-letters/v16n1-html/building_a_movement.html</FONT></FONT></A></DIV><P style="margin: 0.0px 0.0px 0.0px 0.0px"><FONT class="Apple-style-span" face="Verdana"> </FONT></P><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">14. </FONT><B><FONT class="Apple-style-span" face="Verdana">Join MAPS at the World Psychedelic Forum, March 21-24</FONT></B></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font: normal normal normal 12px/normal Verdana; min-height: 15px; "><BR></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Along with Gaia Media, MAPS will be co-sponsoring the World Psychedelic Forum, which will be held in Basel, Switzerland from March 21-23, 2008. Gaia Media is the organization that put together the Spirit of Basel symposium in honor of Albert Hofmann's 100th birthday in January, 2006. </FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; font: normal normal normal 12px/normal Verdana; min-height: 15px; "><BR></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">For more information and to register: </FONT><A href="http://www.psychedelic.info/"><FONT class="Apple-style-span" color="#0027DF"><FONT class="Apple-style-span" face="Verdana">http://www.psychedelik.info</FONT></FONT></A><FONT class="Apple-style-span" face="Verdana">/</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Gaia Media will be hosting a talk in Basel on January 26 featuring Rick Doblin, MAPS-sponsored MDMA/PTSD researcher Peter Oehen, MD, MAPS-sponsored LSD/end-of-life anxiety researcher Peter Gasser, MD, and MAPS Patron Member Vanja Palmers. Stay tuned in for more details.</FONT></DIV><DIV class="MsoNormal"><SPAN style=""><FONT class="Apple-style-span" face="Verdana"> </FONT></SPAN></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">15.</FONT><B><FONT class="Apple-style-span" face="Verdana"> </FONT></B><B><FONT class="Apple-style-span" face="Verdana">Psychedelic Researcher </FONT></B><B><FONT class="Apple-style-span" face="Verdana">John Beresford Dies</FONT></B></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana">Early psychedelic research pioneer John Beresford died on September 2. Beresford, who was born in Britain, resigned his post as an Assistant Professor of Pediatrics at the New York Medical College in 1961 to found the Agora Scientific Trust, the world's first research organization devoted to investigating the effects of LSD.</FONT></DIV><DIV class="MsoNormal"><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><DIV><SPAN class="Apple-style-span" style="border-collapse: separate; -khtml-border-horizontal-spacing: 0px; -khtml-border-vertical-spacing: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; -khtml-text-decorations-in-effect: none; text-indent: 0px; -apple-text-size-adjust: auto; text-transform: none; orphans: 2; white-space: normal; widows: 2; word-spacing: 0px; "><SPAN class="Apple-style-span" style="border-collapse: separate; -khtml-border-horizontal-spacing: 0px; -khtml-border-vertical-spacing: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; -khtml-text-decorations-in-effect: none; text-indent: 0px; -apple-text-size-adjust: auto; text-transform: none; orphans: 2; white-space: normal; widows: 2; word-spacing: 0px; "><DIV><FONT class="Apple-style-span" face="Verdana">*********************</FONT><FONT class="Apple-style-span" face="Verdana"><SPAN style=""></SPAN></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><SPAN style="; text-indent: 28px; "><FONT class="Apple-style-span" face="Verdana">Now that psychedelic research is being approved, the formidable challenge is funding it. </FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana">Since these drugs are off-patent and would not be used on a daily basis, no for-profit pharmaceutical company has demonstrated any interest in sponsoring psychedelic research. Because of Drug War ideology, there is currently no government funding for this research. Plus, most foundations and philanthropists are averse to controversy. </FONT><SPAN style=""><FONT class="Apple-style-span" face="Verdana">Because of the Drug War, this area of study is 35 years behind schedule. </FONT><FONT class="Apple-style-span" face="Verdana"><O:P style=""></O:P></FONT></SPAN><FONT class="Apple-style-span" face="Verdana">For historical reasons, unfortunately, psychedelics remain highly controversial. </FONT><SPAN style=""><SPAN style=""><FONT class="Apple-style-span" face="Verdana">This means society must rely on people like you.</FONT><FONT class="Apple-style-span" face="Verdana"><SPAN style=""></SPAN></FONT></SPAN></SPAN></SPAN></SPAN></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><SPAN style="; text-indent: 28px; "><SPAN style=""><SPAN style=""><SPAN style=""><SPAN style=""><FONT class="Apple-style-span" face="Verdana">You can help make up for lost time by making a tax-deductible contribution today at: <A href="http://www.maps.org/donate">http://www.maps.org/donate</A></FONT></SPAN></SPAN></SPAN></SPAN></SPAN></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Thank you for your generosity and foresight.</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Best Wishes,</FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana">Jag </FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Jag Davies</FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Director of Communications</FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><I style="font-style: italic; "><SPAN class="Apple-style-span" style="font-style: italic; "><SPAN class="Apple-style-span" style="font-style: italic; "><FONT class="Apple-style-span" face="Verdana">The Multidisciplinary Association for Psychedelic Studies</FONT></SPAN></SPAN></I></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">MAPS :: 10424 Love Creek Road :: Ben Lomond, CA 95005</FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">*********************************************</FONT></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><B><FONT class="Apple-style-span" face="Verdana">MAPS: Putting the 'MD' Back in 'MDMA' Since 1986</FONT></B></DIV><DIV style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; "><FONT class="Apple-style-span" face="Verdana">Your Support is Needed! </FONT><SPAN class="Apple-style-span" style="text-decoration: underline; -khtml-text-decorations-in-effect: underline; "><I style="font-style: italic; -khtml-text-decorations-in-effect: underline; "><SPAN class="Apple-style-span" style="font-style: italic; -khtml-text-decorations-in-effect: underline; "><SPAN class="Apple-style-span" style="font-style: italic; -khtml-text-decorations-in-effect: underline; "><A href="http://www.maps.org/catalog"><FONT class="Apple-style-span" face="Verdana">http://www.maps.org/</FONT></A><FONT class="Apple-style-span" face="Verdana">donate</FONT></SPAN></SPAN></I></SPAN></DIV><DIV><B><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></B></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><DIV><FONT class="Apple-style-span" face="Verdana"><BR class="khtml-block-placeholder"></FONT></DIV><FONT class="Apple-style-span" face="Verdana"><BR class="Apple-interchange-newline"></FONT></SPAN></SPAN><FONT class="Apple-style-span" face="Verdana"> </FONT></DIV><FONT class="Apple-style-span" face="Verdana"><BR></FONT></DIV></BODY></HTML>